Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value

With the introduction of new (immuno-)histochemical techniques it is now possible to assess rates of proliferation and apoptosis in brain gliomas using archival paraffin embedded material. As proliferation and apoptosis are related to tumour growth rate quantification of these processes has prognost...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 1999-01, Vol.44 (3), p.255-266
Main Authors: Heesters, M A, Koudstaal, J, Go, K G, Molenaar, W M
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antigens, Nuclear
Apoptosis
Astrocytoma - pathology
Astrocytoma - physiopathology
Brain Neoplasms - genetics
Brain Neoplasms - metabolism
Brain Neoplasms - pathology
Brain Neoplasms - physiopathology
Cell Division
DNA Damage
Glioblastoma - pathology
Glioblastoma - physiopathology
Glioma - pathology
Glioma - physiopathology
Humans
Immunohistochemistry
In Situ Nick-End Labeling
Ki-67 Antigen
Middle Aged
Nuclear Proteins - metabolism
Oligodendroglioma - pathology
Oligodendroglioma - physiopathology
Prognosis
Survival Analysis
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:With the introduction of new (immuno-)histochemical techniques it is now possible to assess rates of proliferation and apoptosis in brain gliomas using archival paraffin embedded material. As proliferation and apoptosis are related to tumour growth rate quantification of these processes has prognostic value and is related to tumour grading. In this study we assessed the proliferation rate by measuring the Ki-67 labelling index using the MIB-1 antibody (MIB-LI) and the apoptotic rate using the in situ labelling of DNA strand breaks with TUNEL (TUNEL-LI) in 315 supratentorial gliomas. MIB-LI and TUNEL-LI in astrocytomas (A) where significantly lower compared to anaplastic astrocytomas (AA), glioblastomas (GBM) and oligodendroglial tumours [oligodendrogliomas (O) and anaplastic oligodendrogliomas (AO)]. MIB-LI and TUNEL-LI were significantly lower in AA compared to GBM. In astrocytic tumours MIB-LI and TUNEL-LI appeared to be correlated. As the distinction between A and AA is of clinical value but can be difficult histomorphologically we analysed the prognostic value of MIB-LI and TUNEL-LI in gliomas with particular emphasis on A and AA. MIB-LI below 10% was of prognostic value in A and AA, O and AO but not in GBM on univariate survival analysis. TUNEL-LI was of no prognostic value. With multivariate survival analysis MIB-LI lost prognostic significance in O and AO. Astrocytomas with a gemistocytic component (AG) are similar to A with respect to survival and MIB-LI and TUNEL-LI. MIB-LI is of independent prognostic value in A and AA. Assessment of MIB-LI in A and AA can be used as an aid in distinguishing A and AA.
ISSN:0167-594X
1573-7373
DOI:10.1023/a:1006398613605